Benjamin Stone

CIK: 0002128786

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TRAX

First Tracks Biotherapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (4 total)

TRAX
First Tracks Biotherapeutics, Inc.
Aug 15, 2026
Award(A)
Performance Stock Units
Direct
60.5K shares-
TRAX
First Tracks Biotherapeutics, Inc.
Aug 2, 2026
Award(A)
Performance Stock Units
Direct
60.5K shares-
TRAX
First Tracks Biotherapeutics, Inc.
May 12, 2026
Award(A)
Restricted Stock Unit
Direct
26.7K shares-
TRAX
First Tracks Biotherapeutics, Inc.
May 12, 2026
Award(A)
Employee Stock Option (right to buy)
Direct
72.3K shares-

		Type	Shares	Price		Ownership
Aug 15, 2026	TRAX First Tracks Biotherapeutics, Inc.	Award(A) Performance Stock Units	60,492	-	-	Direct
Aug 2, 2026	TRAX First Tracks Biotherapeutics, Inc.	Award(A) Performance Stock Units	60,492	-	-	Direct
May 12, 2026	TRAX First Tracks Biotherapeutics, Inc.	Award(A) Restricted Stock Unit	26,700	-	-	Direct
May 12, 2026	TRAX First Tracks Biotherapeutics, Inc.	Award(A) Employee Stock Option (right to buy)	72,300	-	-	Direct

1-4 of 4 transactions

About STONE BENJAMIN

STONE BENJAMIN (SEC CIK 0002128786) files insider reports with the SEC as Chief Business Officer of First Tracks Biotherapeutics, Inc. (TRAX).

Signal8 holds 5 ownership filings by STONE BENJAMIN (2 Form 3, 3 Form 4), filed between Apr 22, 2026 and Aug 18, 2026. Those filings report 4 transactions, from May 12, 2026 to Aug 15, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on STONE BENJAMIN's filings is in SAN DIEGO, CA.

Recent filings by STONE BENJAMIN

Aug 15, 2026: Grant or award of TRAX derivative securities (Form 4, code A).
Aug 2, 2026: Grant or award of TRAX derivative securities (Form 4, code A).
May 12, 2026: Grants or awards of TRAX derivative securities (2 lines, Form 4, code A).

Other insiders filing for First Tracks Biotherapeutics, Inc. (TRAX)

Orwin John A, Director
Ware J. Anthony, Director
Lizzul Paul F., Chief Medical Officer
Faga Daniel, President, CEO
Jain Rita, Director
Schmid John P., Director

How to read Form 4 transaction codes